BiotechTube

Cilofexor

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Nonalcoholic Steatohepatitis (NASH)

Conditions

Nonalcoholic Steatohepatitis (NASH), Primary Sclerosing Cholangitis (PSC)

Trial Timeline

Jul 13, 2016 → Oct 16, 2018

NCT ID
NCT02808312

About Cilofexor

Cilofexor is a phase 1 stage product being developed by Gilead Sciences for Nonalcoholic Steatohepatitis (NASH). The current trial status is completed. This product is registered under clinical trial identifier NCT02808312. Target conditions include Nonalcoholic Steatohepatitis (NASH), Primary Sclerosing Cholangitis (PSC).

What happened to similar drugs?

0 of 6 similar drugs in Nonalcoholic Steatohepatitis (NASH) were approved

Approved (0) Terminated (3) Active (3)
🔄IVA337 + PlaceboInventivaPhase 3
❌SEL + Placebo to match SEL 6 mg + Placebo to match SEL 18 mgGilead SciencesPhase 3
❌SEL + Placebo to match SEL 6 mg + Placebo to match SEL 18 mgGilead SciencesPhase 3
🔄MGL-3196 + PlaceboMadrigal PharmaceuticalsPhase 3
❌Elafibranor + PlaceboGenfitPhase 3
🔄Aramchol free acid + PlaceboGalmed PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT04060147Phase 1Terminated
NCT02808312Phase 1Completed

Competing Products

20 competing products in Nonalcoholic Steatohepatitis (NASH)

See all competitors
ProductCompanyStageHype Score
VK2809 + PlacebosViking TherapeuticsPhase 2
32
TERN-501 + TERN-101Terns PharmaceuticalsPhase 2
32
TERN-101Terns PharmaceuticalsPhase 2
32
TERN-201Terns PharmaceuticalsPhase 1
26
LanifibranorInventivaPhase 2
29
IVA337 + Placebo + EmpagliflozinInventivaPhase 2
29
IVA337 + PlaceboInventivaPhase 3
41
Colesevelam HclDaiichi SankyoPhase 2
35
Tirzepatide + PlaceboEli LillyPhase 2
35
AZD2693AstraZenecaPhase 2
35
Roflumilast + Pioglitazone + Placebo + PlaceboAstraZenecaPhase 2
27
MK-3655 + PlaceboMerckPhase 2
27
Efinopegdutide 20 mg/mL + Semaglutide 1.34 mg/mLMerckPhase 2
35
SEL + Placebo to match SEL 6 mg + Placebo to match SEL 18 mgGilead SciencesPhase 3
32
Seladelpar + PlacebosGilead SciencesPhase 2
27
Firsocostat + FenofibrateGilead SciencesPhase 1
29
GS-9674 + Placebo to match GS-9674Gilead SciencesPhase 2
35
SEL + FIR + CILO + Placebo to match FIR + Placebo to match CILO + Placebo to match SELGilead SciencesPhase 2
35
GS-9450 + GS-9450 PlaceboGilead SciencesPhase 2
35
Semaglutide + Firsocostat + CilofexorGilead SciencesPhase 2
35